r.venkatesan

TL3 Wiki editor · Chennai, IN

Tables and data presentation. Units in the header, not the cells.

Joined 28 October 2024 · last posted 7d · groups: wiki-editors

142 posts, newest first. Showing up to 150.

Deletion sequences: expected mass shifts by residue — the long version Replied, post #18 · Analytics › Impurities & related substances · 21 Jul 2026 · 3 likes The documentation on Deletion sequences is better than this thread and I say that as someone who has posted in the thread.
Immortal time bias in a claims-database study — one year on Replied, post #34 · Evidence › Study critique · 20 Jul 2026 · 9 likes The arithmetic in post #32 is right; the assumption feeding it is the part to check. The pre-specified endpoint being a weaker proxy than you would like is a real…
How shortages have affected compounding permissions Replied, post #54 · Access › Shortages · 20 Jul 2026 · 3 likes Post #52 put the caveat in the right place and I want to underline it. Checked the shortages claim against the primary source this morning. It survives, with a narrower…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #69 · Evidence › Journal club · 18 Jul 2026 · 15 likes Taking post #68 at face value and following it one step further. The most common failure mode is spending fifty minutes on the effect size and ten on the population.…
What a certificate commits its issuer to Replied, post #49 · Analytics › COA interpretation · 17 Jul 2026 · 31 likes A chromatogram supplied as a small image is legible for peak shape and not for baseline detail. That is enough to sanity-check an integration and not enough to…
Journal club: what we got wrong in an earlier session Replied, post #87 · Evidence › Journal club · 15 Jul 2026 · 0 likes Reading order that works for these sessions: registry entry, methods, baseline table, primary result, then abstract last. Reading the abstract first anchors everything…
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #105 · Devices › Syringes & needles · 13 Jul 2026 · 0 likes That is a cleaner way of putting what I was circling around.
Splitting an overlong document into two Replied, post #31 · Documentation › Wiki requests · 9 Jul 2026 · 30 likes Answering the question post #27 raises rather than the one it answers. One caution on splitting an overlong document: everything above assumes the underlying…
About the Oral incretins category Replied, post #5 · Compounds › Oral incretins · 8 Jul 2026 · 0 likes PIONEER programme is phase 3 for oral semaglutide. The trials cover multiple indications and durations. Reading them requires attention to which trial is which because…
How shortages have affected compounding permissions Replied, post #18 · Access › Shortages · 6 Jul 2026 · 11 likes An observation about shortages that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Carryover and the ghost peak from last week's standard — what changed since Replied, post #100 · Analytics › HPLC & UHPLC · 3 Jul 2026 · 4 likes This is the first time the answer has come with its own limits attached. Appreciated.
Why chargeback is not the safety net people assume Replied, post #22 · Sourcing › Payments · 30 Jun 2026 · 0 likes Where I part company with post #19, and it is a narrow parting. The site does not carry prices, payment details or transaction routes, and questions asking for them…
About the Receptor biology category Replied, post #8 · Pharmacology › Receptor biology · 30 Jun 2026 · 14 likes Species differences in receptor pharmacology are substantial in this family, which is one reason rodent data has translated unevenly.
Prescription requirements and telehealth models — a second dataset Replied, post #81 · Sourcing › Regulatory · 27 Jun 2026 · 3 likes Narrowing post #78, because the general version has more than one answer. What I would check first on Prescription requirements and telehealth models is whether the…
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #125 · Practice › Reconstitution · 23 Jun 2026 · 18 likes The best check on any reconstitution calculation is to do it twice by two different routes — mass per volume, then volume per dose — and see whether they agree. They…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #42 · Compounds › Repair & healing peptides · 15 Jun 2026 · 2 likes BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth…
Revisiting: What pooling buys you and what it destroys Replied, post #54 · Evidence › Meta-analyses · 14 Jun 2026 · 1 like The thing about pooling buys that took me longest to accept is that a plausible mechanism is not evidence of an effect. It is a reason to look, not a result.
Secretagogues and glucose tolerance: the mechanistic concern Replied, post #28 · Compounds › Secretagogues & GH axis · 8 Jun 2026 · 27 likes I keep a log for secretagogues and glucose tolerance specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes…
Historical amylin analogues and what happened to them Replied, post #15 · Compounds › Cagrilintide & amylin analogues · 3 Jun 2026 · 21 likes Answering the question post #13 raises rather than the one it answers. Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct…
Reading a trial's population section before its results Replied, post #81 · Evidence › Trials · 3 Jun 2026 · 13 likes Risk of bias: structured appraisal of internal validity. Key things to assess: randomisation method (was it truly random or could someone predict the next assignment),…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #54 · Meta › Announcements · 28 May 2026 · 23 likes Taking post #51 at face value and following it one step further. The rare case here is the one that costs somebody a week, though, and the common case costs everyone…
Spreadsheets: an appreciation — what changed since Replied, post #46 · Lounge › Off topic · 18 May 2026 · 11 likes I have no financial interest in anything named in this thread and I want to say so before I comment on Spreadsheets, because it is the sort of subject where it matters.
Composite endpoints and the component doing the work Started this topic · Evidence › Trials · 16 May 2026 · 27 likes Composite endpoints and the component doing the work Writing it up because I had to work it out twice and would rather nobody else did. Collecting what is known about…
What a certificate commits its issuer to — the long version Replied, post #6 · Analytics › COA interpretation · 10 May 2026 · 18 likes Residual solvent screening is not standard on these documents and its presence is a signal about the manufacturer's own systems rather than about the vial.
Mobile reading experience on long topics Started this topic · Meta › Site feedback · 8 May 2026 · 0 likes Mobile reading experience on long topics Writing it up because I had to work it out twice and would rather nobody else did. Process question, and I have read the…
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #3 · Compounds › Secretagogues & GH axis · 7 May 2026 · 0 likes The arithmetic in post #2 is right; the assumption feeding it is the part to check. Trying to state the GHRH analogues versus ghrelin mimetics position in a way that…
Micro-titration: a disputed topic, argued properly Replied, post #68 · Practice › Dosing & titration · 2 May 2026 · 0 likes I would call the community position on micro-titration likely rather than established, and I would be comfortable defending that hedge.
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #34 · Practice › Interactions · 28 Apr 2026 · 31 likes I had written a reply contradicting post #30 and deleted it. Here is what survived. Gastrointestinal symptoms from one compound can mask or mimic an interaction with…
Revisiting: A field-by-field walk through a certificate of analysis Replied, post #6 · Analytics › COA interpretation · 28 Apr 2026 · 0 likes Reporting rather than recommending, on field-by-field walk through a certificate. What happened is above. Whether it should have is a different question and not one I…
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #23 · Clinical › Bloodwork · 19 Apr 2026 · 3 likes The arithmetic in post #20 is right; the assumption feeding it is the part to check. Liver enzymes drifting has a well-known answer and a correct answer, and the…
0.3 mL versus 0.5 mL versus 1 mL barrels: resolution matters Replied, post #17 · Devices › Syringes & needles · 17 Apr 2026 · 0 likes Adding a note of thanks rather than an opinion. I did not know most of that.
Choosing which test to pay for, given a fixed budget Replied, post #63 · Sourcing › Independent verification · 10 Apr 2026 · 4 likes It does not extend to lots nobody has seen, it is not a recommendation, and it says nothing about anything other than what was measured. That is the shape of it. The…
Grapefruit: why this class is not the class that cares Replied, post #129 · Practice › Interactions · 7 Apr 2026 · 27 likes What I would want before treating grapefruit as settled: the method, the sample, and whether anyone tried to find the opposite result. Two of the three are usually…
Bug report: the reconstitution calculator and a rounding edge case Replied, post #39 · Data & Tools › Calculators · 6 Apr 2026 · 32 likes The most common input error is entering the vial mass in the concentration field. It produces a plausible number, which is why it survives.
Pinch or no pinch, and how needle length changes the answer — the long version Replied, post #36 · Practice › Administration · 26 Mar 2026 · 2 likes Confirming post #33 from a second method, which matters more than confirming it from a second person. Angle of injection: 90 degrees into pinched tissue ensures…
Trust level 3 requirements: a clarification — does this still hold? Replied, post #18 · Meta › Announcements · 19 Mar 2026 · 3 likes This follows post #15 rather than contradicting it. Worth saying publicly: stepping back cleanly and handing over is a service. Documents with an absent maintainer go…
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #12 · Clinical › Bloodwork · 15 Mar 2026 · 24 likes An honest declaration on Liver enzymes drifting: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
Reading a preclinical wound-healing model and its relevance to a human tendon — a second… Replied, post #16 · Compounds › Repair & healing peptides · 8 Mar 2026 · 0 likes Saving this. It is the version I will quote when the question comes round again.
Journal club: PIONEER 6 as a safety trial Replied, post #19 · Evidence › Journal club · 7 Mar 2026 · 1 like On post #18 — agreed on the reasoning, with one qualification. Critical appraisal template: (1) What did the trial set out to estimate? (2) Could the design answer that…
Coming back to: Time to steady state after a dose increase Replied, post #10 · Pharmacology › Pharmacokinetics · 7 Mar 2026 · 0 likes Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein.…
Choosing which test to pay for, given a fixed budget Replied, post #8 · Sourcing › Independent verification · 27 Feb 2026 · 27 likes Post #4 describes the usual case. This is about the unusual one. Repeat testing: if you want to verify the same lot a second time, testing with a different service…
Residual solvents and scavengers: what is looked for — what changed since Replied, post #11 · Analytics › Impurities & related substances · 26 Feb 2026 · 12 likes Thank you for the correction. I would rather find out here than later.
Measurement error in a self-reported exposure Replied, post #69 · Evidence › Study critique · 25 Feb 2026 · 6 likes Post #66 is the version of this I will quote in future. One addition. A criticism that would apply equally to every trial in the field is worth stating once and is not…
Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #15 · Compounds › Cagrilintide & amylin analogues · 19 Feb 2026 · 26 likes Fair, and the limits you put on it are the part I will remember.
The most common factual error about semaglutide on the internet — what changed since Replied, post #23 · Compounds › Semaglutide · 8 Feb 2026 · 3 likes Research-use-only semaglutide is not a licensed medicine, is not manufactured to pharmaceutical standards, and is not approved for human use. That is a statement about…
Second pass at: Adsorptive losses at low concentration, and why dilute solutions are… Replied, post #33 · Practice › Storage & stability · 5 Feb 2026 · 28 likes Clarity is a weak test. A solution can lose a significant fraction of its active content to degradation or adsorption while remaining perfectly clear. I am confident…
Revisiting: Absolute versus relative contraindications Replied, post #18 · Safety › Contraindications · 2 Feb 2026 · 3 likes History of pancreatitis: these compounds can rarely trigger pancreatitis. History of pancreatitis increases relative risk. That is a relative contraindication, not…
Follow-up: Evidence quality in the secretagogue literature: an honest assessment Replied, post #11 · Compounds › Secretagogues & GH axis · 31 Jan 2026 · 13 likes Answering the question post #7 raises rather than the one it answers. The most useful single question to ask about any compound in this family is what the published…
Price changes over 2025 and 2026, tabulated and dated — does this still hold? Replied, post #76 · Access › Pricing · 31 Jan 2026 · 22 likes Clear enough that I do not think I have a follow-up, which is unusual.
Gastro-oesophageal reflux: improving or worsening? Replied, post #15 · Clinical › Comorbidities · 30 Jan 2026 · 0 likes Where a condition is well controlled and where it is not are different questions and the published data rarely distinguishes them.
AOD-9604 and the fragment hypothesis, revisited Replied, post #40 · Compounds › Other compounds · 4 Jan 2026 · 16 likes A request rather than an answer: could whoever has the primary source for AOD-9604 post it? I have seen the claim three times this month and each version had lost a…
Ultrasound and skinfolds: operator dependence in practice — what changed since Replied, post #5 · Outcomes › Body composition · 3 Jan 2026 · 31 likes Before the thread moves on from Ultrasound and skinfolds — what is the sample size behind the claim? I am not being difficult; I have seen the same figure quoted from…
Dizziness on standing and the electrolyte explanation — does this still hold? Replied, post #30 · Practice › Side effects · 30 Dec 2025 · 24 likes Post #27 is right about the mechanism and I think understates the practical bit. An observation about Dizziness on standing that I cannot explain and am posting anyway,…
Half-life, steady state, and accumulation worked through — a second dataset Replied, post #47 · Pharmacology › Pharmacokinetics · 28 Dec 2025 · 0 likes Loading doses are not used in this class and the pharmacokinetic reason is tolerability rather than efficacy. A loading dose would reach steady state faster and would…
Heterogeneity as information rather than as a nuisance Replied, post #30 · Evidence › Meta-analyses · 18 Dec 2025 · 2 likes Nobody has said the unglamorous part of heterogeneity yet, so: most of the variation is explained by things that are boring to write about and easy to check.
Request: export my own posts — one year on Replied, post #22 · Meta › Feature requests · 14 Dec 2025 · 0 likes Taking post #19 at face value and following it one step further. Small methodological point on export: repeating a measurement is cheap and resolves most of what is…
Aggregates and why a purity assay may miss them entirely Started this topic · Analytics › Impurities & related substances · 8 Dec 2025 · 0 likes Aggregates and why a purity assay may miss them entirely Writing it up because I had to work it out twice and would rather nobody else did. I would like to disagree…
Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #57 · Compounds › Semaglutide · 28 Nov 2025 · 0 likes Injection site does not appear to matter much for semaglutide exposure. The published comparisons of abdomen, thigh and upper arm found differences small enough to be…
Thyroid function tests during substantial weight change Replied, post #145 · Clinical › Bloodwork · 23 Nov 2025 · 6 likes Repeat before acting is standard practice for an isolated abnormal result on most analytes, and it is standard for a reason. Nothing above should be read as advice…
Tracking that stops updating and then resumes — the long version Replied, post #41 · Sourcing › Logistics · 21 Nov 2025 · 0 likes I read post #37 twice before replying, because I had assumed the opposite. A tracking gap at a customs facility is the most common cause of an unexpectedly long transit…
Pen dose counters: what a click does and does not guarantee Replied, post #93 · Devices › Pens & autoinjectors · 18 Nov 2025 · 20 likes Disposal of a used pen is a sharps question even where the needle is retracted, and local rules vary more than people expect. Second-hand, so weight it accordingly.
Second pass at: A reconstituted vial's beyond-use date and the reasoning behind common… Replied, post #2 · Practice › Storage & stability · 18 Nov 2025 · 0 likes Fine by me. I had wanted a stronger conclusion and there is not one available.
[2026 update] What steady state means for the decision to escalate Replied, post #85 · Practice › Dosing & titration · 14 Nov 2025 · 32 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.…
Reading SURMOUNT-1 without the press release Replied, post #51 · Compounds › Tirzepatide · 31 Oct 2025 · 5 likes SURMOUNT-4 used a randomised withdrawal design: everyone titrated, then those on maintenance were randomised to continue or placebo. Continuation maintained effect;…
Why an oral GLP-1 agonist is a formulation achievement more than a chemistry one Replied, post #10 · Compounds › Oral incretins · 19 Oct 2025 · 12 likes Taking post #9 at face value and following it one step further. The practical argument for an oral is adherence, and the published adherence data is less flattering…
Revisiting: GLP-1 receptor distribution: central and peripheral Replied, post #51 · Pharmacology › Receptor biology · 12 Oct 2025 · 0 likes Glucagon receptor agonism: glucagon receptor agonism increases energy expenditure and promotes hepatic fat oxidation. The mechanism is distinct from GLP-1 and GIP…
Warfarin and altered intake: the monitoring argument — the long version Replied, post #30 · Practice › Interactions · 11 Oct 2025 · 8 likes Everything in post #29 holds. The case it does not cover is the one I have. Warfarin and altered intake is a good example of a question where the honest answer is…
What a purity-only report leaves out Replied, post #40 · Sourcing › Independent verification · 9 Oct 2025 · 22 likes Post #39 is right about the mechanism and I think understates the practical bit. Purity-only is well covered in the tag pages, and the older discussions are better than…
A preprint whose numbers changed substantially at publication Replied, post #57 · Evidence › Preprints · 18 Sep 2025 · 21 likes Where numbers change between preprint and published version, the changes are not random. They tend toward a smaller effect and a more carefully hedged claim.
Reading SURMOUNT-1 without the press release Replied, post #8 · Compounds › Tirzepatide · 13 Sep 2025 · 14 likes Adding a reference point for reading SURMOUNT-1 without the press. Mine is a single case, collected without controls, and I am posting the method alongside it so it can…
Second pass at: LOD and LOQ: definitions people get wrong Replied, post #48 · Analytics › Method validation · 13 Sep 2025 · 16 likes Everything in post #46 holds. The case it does not cover is the one I have. Why two laboratories may disagree: after validating the same method, they may still report…
Aggregated purity results across four services, with caveats — a second dataset Replied, post #98 · Data & Tools › Datasets · 10 Sep 2025 · 0 likes Answering the question post #94 raises rather than the one it answers. Sample size is not the only thing that determines what a dataset can support. Selection is…
Aggregated purity results across four services, with caveats — a second dataset Replied, post #73 · Data & Tools › Datasets · 9 Sep 2025 · 11 likes The confident answers on Aggregated purity results across four and the well-sourced answers are not the same answers, which is the most useful thing I have learned…
EU-wide position versus national implementation Replied, post #26 · Regional › European Union · 16 Aug 2025 · 2 likes Post #25 is the version of this I will quote in future. One addition. Nothing here is medical or legal advice, and this subcategory in particular attracts questions…
Revisiting: List price versus negotiated price versus what you pay Replied, post #10 · Access › Pricing · 5 Aug 2025 · 1 like Where a price includes consultation, device and follow-up, saying so makes a comparison possible. Most quoted figures do not.
A request that was declined, and the reasoning — a second dataset Replied, post #2 · Documentation › Wiki requests · 4 Aug 2025 · 8 likes Documents that are mostly a worked example age better than documents that are mostly a summary, because the arithmetic does not change.
How to research a compound with no human data without deceiving yourself Replied, post #96 · Compounds › Other compounds · 4 Aug 2025 · 32 likes Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its…
How to research a compound with no human data without deceiving yourself Replied, post #81 · Compounds › Other compounds · 3 Aug 2025 · 8 likes When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and…
Revisiting: Why a compound being unapproved is not the same as being illegal to possess Replied, post #61 · Sourcing › Regulatory · 26 Jul 2025 · 0 likes Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption. The…
System suitability injections: if they failed, the run did not happen Replied, post #16 · Analytics › HPLC & UHPLC · 21 Jul 2025 · 2 likes System suitability is not paperwork. If the replicate injections failed, the run did not happen — the numbers from it are uninterpretable rather than approximate. That…
Second pass at: A history of disordered eating: proceeding carefully Replied, post #90 · Wellbeing › Mental health · 15 Jul 2025 · 0 likes Counterpoint on history of disordered eating, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the…
[2026 update] What the GIP component of tirzepatide is thought to contribute, and how… Replied, post #88 · Compounds › Tirzepatide · 15 Jul 2025 · 25 likes Categorical response thresholds — the proportion reaching ten, fifteen or twenty per cent reduction — are more persuasive and less informative than the mean. They…
Distinguishing a deletion sequence by mass alone — the long version Replied, post #33 · Analytics › Mass spectrometry · 13 Jul 2025 · 12 likes Mass error in parts per million is (observed minus theoretical) divided by theoretical, times a million. On a high-resolution instrument a low single-digit figure is…
EU-wide position versus national implementation Replied, post #17 · Regional › European Union · 12 Jul 2025 · 2 likes Building on post #15 rather than restating it. Eu-wide position versus national implementation is a question about a distribution, not about a value, and treating it as…
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists Replied, post #41 · Compounds › Cagrilintide & amylin analogues · 10 Jul 2025 · 0 likes That is clearer than the version I had in my head. Thank you.
Substitution between formats during a shortage Replied, post #19 · Access › Shortages · 7 Jul 2025 · 2 likes I had written a reply contradicting post #15 and deleted it. Here is what survived. The thing about substitution between formats that took me longest to accept is that…
Follow-up: The decimal-point error, and the habit that catches it Replied, post #21 · Practice › Reconstitution · 6 Jul 2025 · 0 likes Confirming post #20 from a second method, which matters more than confirming it from a second person. Decimal-point error has a well-known answer and a correct answer,…
Repeatability versus intermediate precision Replied, post #131 · Analytics › Method validation · 3 Jul 2025 · 0 likes Post #130 and I disagree about the size of the effect, not about the direction. The limit of quantitation determines what the impurity table can honestly contain. Peaks…
Second pass at: Pharmacy supply in the UK and the questions you will be asked Replied, post #48 · Regional › UK & Ireland · 25 Jun 2025 · 5 likes The most useful contribution is a link to the current official page with the date you accessed it. That survives; a paraphrase does not. This has been discussed before…
The CagriSema phase 2 paper and what a fixed combination buys — the long version Replied, post #130 · Compounds › Cagrilintide & amylin analogues · 18 Jun 2025 · 1 like That reframing is the whole thing. The facts I already had.
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #41 · Compounds › Repair & healing peptides · 16 Jun 2025 · 11 likes I would call the community position on TB-500 and thymosin beta-4 likely rather than established, and I would be comfortable defending that hedge.
Coming back to: Why quantitation is the hard part, not detection Replied, post #27 · Analytics › Home & field testing · 16 Jun 2025 · 16 likes The right question for any home test is: what physical quantity does it measure, and what would have to be true for that quantity to answer your question? Most…
Distinguishing a deletion sequence by mass alone — the long version Replied, post #24 · Analytics › Mass spectrometry · 2 Jun 2025 · 27 likes Answering the question post #22 raises rather than the one it answers. For a compound with no reference standard in circulation, an observed mass is much more useful…
Half-life, steady state, and accumulation worked through Replied, post #24 · Pharmacology › Pharmacokinetics · 26 May 2025 · 5 likes Post #21 is right about the mechanism and I think understates the practical bit. Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense,…
Travel coolers and how long they really hold — the long version Replied, post #9 · Devices › Cold chain · 20 May 2025 · 4 likes Post #7 put the caveat in the right place and I want to underline it. A temperature indicator that has tripped tells you a threshold was crossed. It does not tell you…
Why fasting instructions for oral semaglutide are not optional advice — does this still… Replied, post #31 · Compounds › Oral incretins · 13 May 2025 · 10 likes Why an oral formulation is a formulation achievement: the molecule is the same but the tablet is novel. Getting a peptide across the gastric epithelium at usable…
Food effects on oral incretin absorption: what is documented Replied, post #2 · Compounds › Oral incretins · 11 May 2025 · 14 likes The opening post and I disagree about the size of the effect, not about the direction. Why administration conditions matter for oral semaglutide and not for…
Lean mass preservation: what the evidence supports Replied, post #9 · Outcomes › Body composition · 9 May 2025 · 0 likes Photographs under fixed lighting and posture are a genuine record and are the hardest of these to standardise. I would call that likely rather than established.
What SELECT changed about how semaglutide is discussed, and what it did not Replied, post #110 · Compounds › Semaglutide · 9 May 2025 · 5 likes Bookmarking this. I will come back when I have something worth adding.
Antibiotics and a course of something with delayed emptying Replied, post #32 · Practice › Interactions · 2 May 2025 · 23 likes Post #28 put the caveat in the right place and I want to underline it. Careful with the language on antibiotics. "Not detected" and "not present" are different findings…
A supplier that answers analytical questions with restated claims Replied, post #67 · Sourcing › Red flags · 30 Apr 2025 · 4 likes My experience of supplier contradicts the reply above. I am posting it as a data point rather than as a refutation, because one person's experience is exactly that.
Reading an MS report that only gives you a single number Replied, post #56 · Analytics › Mass spectrometry · 18 Apr 2025 · 7 likes Confirming post #55 from a second method, which matters more than confirming it from a second person. Quantitation by MS: most quantitation is done by LC-UV detection…
Second pass at: Cross-border purchase within the EU: the actual rules Replied, post #130 · Access › International · 28 Mar 2025 · 6 likes Picking up post #127: that is the part I would want checked first. Summaries lag badly in this area. Where a decision matters, read the current official document rather…
Adducts: sodium, potassium, and the peak you did not expect Replied, post #42 · Analytics › Mass spectrometry · 22 Mar 2025 · 5 likes Trifluoroacetate adducts are common in material purified with TFA and are one reason a mass spectrum from a peptide can look busier than expected.
Follow-up: Journal club: the retatrutide phase 2 obesity paper Replied, post #7 · Evidence › Journal club · 20 Mar 2025 · 5 likes The most useful reply I ever got about retatrutide phase 2 obesity paper was a request to state my units. It sounds like pedantry and it has saved me twice.
Maintainer handover: how it works Replied, post #51 · Meta › Wiki maintenance · 17 Mar 2025 · 6 likes Post #47 describes the usual case. This is about the unusual one. Review dates: each maintained page has a review date (the date by which it should be checked). If a…
Biased agonism: a real phenomenon, an over-used explanation Replied, post #105 · Pharmacology › Receptor biology · 15 Mar 2025 · 24 likes Everything in post #101 holds. The case it does not cover is the one I have. Biased agonism is a question about a distribution, not about a value, and treating it as a…
UK access routes, dated and sourced — a second dataset Replied, post #47 · Regional › UK & Ireland · 7 Mar 2025 · 0 likes Taking post #44 at face value and following it one step further. MHRA is the regulator. Licensed incretin analogues are prescription-only medicines. NHS and private…
Pharmaceutical compounding rules, summarised from primary sources Replied, post #132 · Sourcing › Regulatory · 5 Mar 2025 · 0 likes I would call the community position on pharmaceutical compounding rules likely rather than established, and I would be comfortable defending that hedge.
Validating a method you did not develop — does this still hold? Replied, post #26 · Analytics › Method validation · 20 Feb 2025 · 4 likes Where a pharmacopoeial monograph exists, a method that follows it inherits a great deal of assurance. Almost nothing discussed here has one.
Reading an MS report that only gives you a single number Replied, post #12 · Analytics › Mass spectrometry · 17 Feb 2025 · 2 likes Positional isomers and epimers are mass-identical. Any argument that a mass result rules them out is wrong, and it is the commonest overclaim in this subcategory.
What we do not know about retatrutide, listed explicitly Replied, post #86 · Compounds › Retatrutide · 7 Feb 2025 · 0 likes Taking post #85 at face value and following it one step further. Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is…
A certificate whose chromatogram axes do not match its stated method Replied, post #4 · Sourcing › Red flags · 6 Feb 2025 · 1 like Documentation quality as a signal: a supplier that reports method identifiers, distinguishes specification from result, and states the counter-ion form is telling you…
Anaesthesia and elective surgery: the aspiration question — does this still hold? Replied, post #21 · Practice › Interactions · 1 Feb 2025 · 0 likes Post #17 and I disagree about the size of the effect, not about the direction. On Anaesthesia and elective surgery the community has more anecdote than the confidence…
Protein density versus volume when you cannot eat much Replied, post #44 · Nutrition & Training › Protein & intake · 31 Jan 2025 · 27 likes Coming back to post #40, because the follow-up matters more than the original answer. Micronutrient adequacy becomes a real question at very low total intake and is…
HbA1c lag and what it can and cannot tell you at eight weeks Replied, post #4 · Clinical › Bloodwork · 30 Jan 2025 · 1 like Adding thanks rather than a view. I do not have a view worth the space.
Semaglutide half-life: where the 165 to 184 hour figure comes from — what changed since Replied, post #93 · Compounds › Semaglutide · 27 Jan 2025 · 0 likes A definition problem is doing most of the work in this Semaglutide half-life discussion. Once the term is pinned down I suspect the disagreement mostly goes away and…
When to suspect the method rather than the sample Replied, post #70 · Analytics › Method validation · 23 Jan 2025 · 25 likes Post #68 describes the usual case. This is about the unusual one. A stability-indicating method is one demonstrated to resolve the analyte from its degradation…
Identical chromatograms across two different lots Replied, post #79 · Sourcing › Red flags · 20 Jan 2025 · 1 like What I can speak to on identical chromatograms is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.
Recovery when intake is low: what to cut first Replied, post #68 · Nutrition & Training › Resistance training · 13 Jan 2025 · 12 likes Post #65 is the version of this I will quote in future. One addition. Recovery capacity falls with energy availability, so a programme that worked at maintenance may be…
[2026 update] Lipid changes during rapid weight loss: the expected trajectory Replied, post #4 · Clinical › Bloodwork · 30 Dec 2024 · 0 likes The opening post is right about the mechanism and I think understates the practical bit. Adding a small correction to the Lipid changes during rapid weight summary…
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #80 · Compounds › Semaglutide · 23 Dec 2024 · 22 likes The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice.…
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #160 · Analytics › COA interpretation · 22 Dec 2024 · 0 likes The arithmetic in post #157 is right; the assumption feeding it is the part to check. "Not less than 98 per cent" is a specification. "98.3 per cent" is a result. A…
[2026 update] Step therapy requirements and how to satisfy them Replied, post #76 · Access › Insurance & coverage · 18 Dec 2024 · 7 likes Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves…
Transit times by route, from a logged dataset — the long version Replied, post #40 · Sourcing › Logistics · 18 Dec 2024 · 0 likes Anyone deciding whether a delay is a problem should ask what would change if they waited another week. Usually the answer is nothing. The interesting part of this is…
Revisiting: Moderation log format change Replied, post #45 · Meta › Announcements · 28 Nov 2024 · 15 likes I read post #43 twice before replying, because I had assumed the opposite. The bit of Moderation log format change that nobody enjoys is that the answer changes…
SURPASS-2 and the comparator dose question that will not go away Replied, post #66 · Compounds › Tirzepatide · 28 Nov 2024 · 25 likes Picking up post #63: that is the part I would want checked first. Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply…
Fixed versus detachable needles: the trade-offs Replied, post #18 · Devices › Syringes & needles · 25 Nov 2024 · 0 likes Filter needles are for drawing from glass ampoules where particulate is a real risk. For a stoppered vial they add dead volume in exchange for very little.
A vial that will not fully dissolve: what to check and in what order Replied, post #6 · Practice › Reconstitution · 15 Nov 2024 · 0 likes Adding the measurement that post #3 says would settle it. A 10 mg vial reconstituted three different ways: 1 mL diluent gives 10 mg/mL, 2 mL gives 5 mg/mL, 4 mL gives…
Reading a preclinical wound-healing model and its relevance to a human tendon Replied, post #58 · Compounds › Repair & healing peptides · 15 Nov 2024 · 0 likes Adding the measurement that post #55 says would settle it. Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims…
Time to steady state after a dose increase Replied, post #135 · Pharmacology › Pharmacokinetics · 6 Nov 2024 · 17 likes Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule…
How to ask for a dose change without antagonising anyone — what changed since Replied, post #21 · Clinical › Prescriber conversations · 1 Nov 2024 · 0 likes Building on post #19 rather than restating it. Ask what the follow-up plan is and when the next review is. That single question prevents most of the drift people report…
Revisiting: Moderation log format change Replied, post #9 · Meta › Announcements · 28 Oct 2024 · 0 likes Nothing to add, except that this is the answer I would give if asked.
Coming back to: Research-use-only labelling: what it means and what it does not Replied, post #11 · Sourcing › Regulatory · 22 Oct 2024 · 22 likes Practical experience of Research-use-only labelling, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what…
Gallbladder disease risk with rapid weight loss Replied, post #13 · Clinical › Comorbidities · 26 Sep 2024 · 0 likes This is the answer, and the reason it is the answer is the more useful part.
Promotion criteria, and the one that stops most nominations Replied, post #65 · Documentation › Doc review · 19 Sep 2024 · 4 likes An honest declaration on promotion criteria: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
When a red flag was a misunderstanding, and the retraction Replied, post #19 · Sourcing › Red flags · 19 Sep 2024 · 20 likes I had written a reply contradicting post #17 and deleted it. Here is what survived. The most useful contribution to this subcategory is a resolved case written up with…
Revisiting: How to bring a laboratory report to an appointment usefully Replied, post #16 · Clinical › Bloodwork · 8 Sep 2024 · 24 likes I had written a reply contradicting post #14 and deleted it. Here is what survived. I changed my mind about bring a laboratory after someone here asked me for the…
Correlation in a self-tracked dataset: what it can support Replied, post #58 · Research Methods › Statistics · 22 Aug 2024 · 13 likes For anyone finding this later: the short answer on correlation is that it depends on one thing, and the rest of the thread is people identifying which thing.
Guidelines revision: what changed and why Replied, post #49 · Meta › Announcements · 26 Jul 2024 · 9 likes I had written a reply contradicting post #48 and deleted it. Here is what survived. Speaking only to guidelines revision as I have actually seen it, rather than as it…
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Replied, post #88 · Practice › Dosing & titration · 9 Jul 2024 · 32 likes Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a…
Second pass at: Journal club: LEADER as the historical anchor Replied, post #9 · Evidence › Journal club · 8 Jul 2024 · 0 likes What I can speak to on LEADER is narrow, so I will keep it narrow rather than generalising from it. Beyond that boundary I do not know.